Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly wants the public to know it’s more than ... However, during that time, Lilly has embarked on a greater corporate brand-building effort that it hopes will elevate its reputation as a whole.

INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly said on Monday it sued ... which is also approved to treat type 2 diabetes under the brand name Mounjaro. In its most recent filings, Lilly said MangoRx was selling an oral version ...

Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings ... cold-chain products across a dozen different dose and brand combinations. We estimate this inventory decrease impacted ...